Application of transporter assays for drug discovery and development: an update of the literature

被引:0
|
作者
Volpe, Donna A. [1 ]
机构
[1] US FDA, Div Appl Regulatory Sci, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
关键词
Drug transporters; uptake; efflux; in vitro; assays; INTESTINAL EPITHELIAL-CELLS; PRIMARY HUMAN HEPATOCYTES; IN-VITRO; P-GLYCOPROTEIN; DEPENDENT INHIBITION; PROTEIN EXPRESSION; GENE-EXPRESSION; MDCK CELLS; BCRP; MDR1;
D O I
10.1080/17460441.2024.2387790
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Determining whether a new drug is a substrate, inhibitor or inducer of efflux or uptake membrane transporters has become a routine process during drug discovery and development. In vitro assays are utilized to establish whether a new drug has the potential to be an object (substrate) or precipitant (inhibitor, inducer) in transporter-mediated clinical drug-drug interactions. The findings from these in vitro experiments are then used to determine whether further in vivo drug interaction studies are necessary for a new drug. Areas covered: This article provides an update on in vitro transporter assays, focusing on new uses of transfected cells, time-dependent inhibition, transporter induction, and complex model systems. Expert opinion: The newer in vitro assays add to the toolbox in defining new drugs as transporter substrates, inhibitors, or inducers. Complex models such as spheroids, organoids, and microphysiological systems require standardization and further research with model transporter substrates and inhibitors. In drug discovery, the more traditional transporter assays may be employed as substrate and inhibitor screening assays. In drug development, more complex cell models can be employed in later drug development to better understand how transporter(s) are involved in the absorption, distribution, and excretion of new drugs.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Application of nitric oxide in drug discovery and development
    Bryan, Nathan S.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2011, 6 (11) : 1139 - 1154
  • [32] APPLICATION OF IN SILICO DMPK IN DRUG DISCOVERY AND DEVELOPMENT
    Broccatelli, Fabio
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S12 - S12
  • [33] Development of synthetic methodologies and their application in drug discovery
    Shah, Bhahwal Ali
    Boons, Geert Jan
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [34] Zebrafish apoptosis assays for drug discovery
    Parng, C
    Anderson, N
    Ton, C
    McGrath, P
    [J]. ZEBRAFISH: 2ND EDITION CELLULAR AND DEVELOPMENTAL BIOLOGY, 2004, 76 : 75 - +
  • [35] In Vitro Solubility Assays in Drug Discovery
    Kerns, Edward H.
    Di, Li
    Carter, Guy T.
    [J]. CURRENT DRUG METABOLISM, 2008, 9 (09) : 879 - 885
  • [36] Drug discovery and evaluation pharmacological assays
    Stanford, SC
    [J]. ADDICTION BIOLOGY, 1999, 4 (01) : 100 - 100
  • [37] cAMP assays in GPCR drug discovery
    Vasudevan, Neelakantan T.
    [J]. G PROTEIN-COUPLED RECEPTORS, 2ND EDITION, PT A, 2017, 142 : 51 - 57
  • [38] Cell death assays for drug discovery
    Kepp, Oliver
    Galluzzi, Lorenzo
    Lipinski, Marta
    Yuan, Junying
    Kroemer, Guido
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (03) : 221 - 237
  • [39] Cell death assays for drug discovery
    Oliver Kepp
    Lorenzo Galluzzi
    Marta Lipinski
    Junying Yuan
    Guido Kroemer
    [J]. Nature Reviews Drug Discovery, 2011, 10 : 221 - 237
  • [40] Discovery and development of IgE assays
    Johansson, SGO
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 1997, 27 : 60 - 63